<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036893</url>
  </required_header>
  <id_info>
    <org_study_id>M0001-C101</org_study_id>
    <nct_id>NCT01036893</nct_id>
  </id_info>
  <brief_title>M0001 Effects on Oral Contraceptive Plasma Levels</brief_title>
  <official_title>The Effect of Prucalopride on the Plasma Levels of Oral Contraceptives (Ethinylestradiol and Norethisterone) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Movetis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FOCUS GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Movetis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, two-way cross-over drug-drug interaction Phase I trial.&#xD;
&#xD;
      The objectives of this phase I trial are to investigate in healthy female subjects:&#xD;
&#xD;
        -  the effect of prucalopride on the absorption of ethinylestradiol and norethisterone&#xD;
           acetate, the active constituents of several oral contraceptives, after the first dose of&#xD;
           prucalopride.&#xD;
&#xD;
        -  the effect of multiple oral dosing of 2 mg prucalopride, for 6 days o.d. (steady state),&#xD;
           on the pharmacokinetics of ethinylestradiol and norethisterone acetate.&#xD;
&#xD;
      This trial will be conducted in healthy females of child bearing potential, i.e. females aged&#xD;
      between 18 and 45 years (pre-menopausal).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma levels oral contraceptives</measure>
    <time_frame>first days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels oral contraceptives after steady state</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>oral contraceptives without prucalopride</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>oral contraceptives with prucalopride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prucalopride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prucalopride</intervention_name>
    <description>prucalopride 2 mg oral dosing o.d. for 6 days</description>
    <arm_group_label>oral contraceptives with prucalopride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Subjects who meet all of the following criteria are eligible for this trial:&#xD;
&#xD;
          1. Healthy females, aged between 18 and 45 years extremes included, who have regular&#xD;
             menstrual cycle of 28 Â± 3 days for the last 6 months.&#xD;
&#xD;
          2. Adequate use of non-hormonal birth control (double-barrier method (e.g. condom and&#xD;
             spermicide, cervical cap and spermicide) or sterilization or vasectomy of the partner&#xD;
             or certified abstinence).&#xD;
&#xD;
          3. Subjects are not smoking for at least 6 months prior to selection.&#xD;
&#xD;
          4. A body mass index (BMI) between 18 and 27 kg/m2, extremes included.&#xD;
&#xD;
          5. The subject is in good health based on a pre-trial physical and gynaecological&#xD;
             examination, medical history, anamnesis, electrocardiogram (ECG) and the results of&#xD;
             biochemistry, coagulation or haematology tests or a urinalysis carried out within 4&#xD;
             weeks before the start of the trial. If the results of the biochemistry, coagulation&#xD;
             or haematology tests or the urinalysis are not within the laboratory's reference&#xD;
             ranges the subject will be included only on condition that the investigator judges&#xD;
             that the deviations are not clinically significant.&#xD;
&#xD;
          6. Subjects voluntarily signed written Informed Consent Form (ICF) in accordance with the&#xD;
             regional laws or regulations, prior to the first trial related activity, indicating an&#xD;
             understanding of the purpose of this trial.&#xD;
&#xD;
          7. Subjects are willing to adhere to the treatment regimen and trial procedures described&#xD;
             in this protocol.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Subjects meeting any of the following criteria will be excluded from the trial:&#xD;
&#xD;
          1. History, evidence or suspicion of alcohol or drug abuse (screening and Day -1).&#xD;
&#xD;
          2. History or evidence of cardiac arrhythmias, bronchospastic or cardiovascular disease&#xD;
             (e.g. ischemic heart disease or cerebrovascular accident), hepatic or&#xD;
             gastrointestinal, renal or endocrine (diabetes mellitus, thyrotoxicosis), or&#xD;
             neurological (Parkinsonism) or psychiatric, gynaecological or dermatological disease,&#xD;
             drug allergy.&#xD;
&#xD;
          3. Clinical significant abnormal ECG-intervals of morphology of the ECG, QT &gt;500 ms or&#xD;
             QTcB&gt;470 ms.&#xD;
&#xD;
          4. Use of concomitant medication or oral contraceptives within 6 weeks prior to&#xD;
             screening, or any hormonal depot-device within 6 months prior to screening . All&#xD;
             medication, with the exception of paracetamol should be stopped.&#xD;
&#xD;
          5. Participation in an investigational drug trial in 30 days prior to the first visit.&#xD;
&#xD;
          6. Donation of blood in the 60 days preceding the first visit.&#xD;
&#xD;
          7. Pregnancy (as confirmed by a HCG test during screening and at Day 1 of each treatment&#xD;
             session before dosing) or breast feeding.&#xD;
&#xD;
          8. Subjects with positive results for HIV, hepatitis B or C at screening.&#xD;
&#xD;
          9. Known allergy to the trial drugs ingredients/excipients.&#xD;
&#xD;
         10. Subject has contraindications for the use of oral contraceptives (known or suspected&#xD;
             active venous thrombo-embolic disorder, known or suspected hormone dependent&#xD;
             malignancies, undiagnosed vaginal bleeding, coagulation disorders, menstrual cycle&#xD;
             depending migraine, lipid metabolism disorders, hepatic disorders)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FOCUS GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>D-41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>December 18, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>May 16, 2011</last_update_submitted>
  <last_update_submitted_qc>May 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Remi Van Den Broeck, Chief Development Officer</name_title>
    <organization>Movetis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prucalopride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

